APA Annual Meeting

NEW YORK CITY—The investigational olanzapine-samidorphan drug ALKS 3831 did not outperform olanzapine alone in reducing alcohol use in patients with schizophrenia and alcohol use disorder, but it did improve symptoms of schizophrenia, a study found.


nasal spray

NEW YORK CITY—Esketamine nasal spray reduced symptoms in patients with treatment-resistant depression in two Phase 3 clinical trials, but the decrease was statistically significant in only one of the trials.

NEW YORK CITY—Early evidence suggests the tuberculosis drug D-cycloserine may ease treatment-resistant depression and supports further trials on its efficacy as a novel antidepressant, a research review found.


NEW YORK CITY—One year’s treatment with a particular long-acting injectable improved function and sleep quality in 90 adults with schizophrenia, according to new research.

NEW YORK CITY—Exercise should be prescribed—not just recommended—for patients with depression, using specific techniques to boost patient buy-in and adherence, a team of military clinicians said at the American Psychiatric Association’s annual meeting.

NEW YORK CITY—Physician well-being, burnout, and innovation through technology will be prominent themes at this year’s annual American Psychiatric Association (APA) meeting, being held here May 5-9.